Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
(Dorland Global Public Relations) Avalon Pharmaceuticals announces the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. Beta-catenin is one of the most commonly activated cancer pathways and is known to play a key role in the initiation and progression of cancer, particularly colon cancer. The compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. Avalon plans to begin clinical testing of AVN316 in patients in 2009.
Republican presidential candidate Sen. John McCain has chosen Gov. Sarah Palin to be his running mate. She would be the first woman to serve on a Republican presidential ticket.
AFP - Nigerian President Umaru Yar'Adua's anti-corruption drive has claimed another scalp with news Friday of the arrest of an ex-governor who allegedly embezzled millions of dollars of state funds.
AP - The NBA officially handed over the Seattle franchise to Oklahoma City about two months ago, and three trucks arrived downtown at headquarters on Friday.
